Absci Corporation (ABSI)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Absci: Positive Ph1 Data ABS-201 AGA And Several Catalysts Inbound (Upgrade)
Absci Corporation is upgraded to “Buy” following positive interim Phase 1 data for ABS-201 in androgenetic alopecia [AGA]. ABS-201 demonstrated an excellent PK profile, enabling infrequent dosing [2–3 injections per 6 months] and strong safety/tolerability in SAD cohorts. Upcoming catalysts include 13-week interim proof-of-concept data in 2H 2026 and 26-week topline results in early 2027 for ABS-201 in AGA.
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.
Absci Corporation (ABSI) Q2 2026 Earnings Call Transcript
Absci Corporation (ABSI) Q2 2026 Earnings Call Transcript
Absci Q2 Earnings Call Highlights
Absci NASDAQ: ABSI outlined progress in its clinical program for ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for development in endometriosis, while reporting a larger cash balance following a June equity offering and strategic investment from Eli Lilly.
Are Medical Stocks Lagging ABSCI CORP (ABSI) This Year?
Here is how Absci Corporation (ABSI) and Acadia Healthcare (ACHC) have performed compared to their sector so far this year.
Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in ABSCI CORP (ABSI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy
Does Absci Corporation (ABSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study
Absci stock jumps 36% as interim phase I hair loss study data show ABS-201 is well tolerated and pharmacokinetics support the potential for infrequent dosing.
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?
ABSCI CORP (ABSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Absci Corporation (ABSI) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Absci Corporation (ABSI) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
